Navigation Links
Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
Date:2/11/2010

CAMBRIDGE, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP; Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida. Data from a pediatric subgroup of this study and five year follow-up results from a long-term Phase I/II extension study (TKT025 EXT) conducted in adults were also reported and add to the available data on the long-term safety and efficacy of velaglucerase alfa in patients with Type 1 Gaucher disease.

Both studies (TKT032 and TKT025 EXT) met their primary end-points.

Additionally, Shire reported important findings from a study that compared patient antibody response to velaglucerase alfa and imiglucerase. All patients enrolled in the velaglucerase alfa Phase III clinical studies underwent a comprehensive panel of tests that were developed and validated to assess antibody response. In each study, samples were first screened using an electrochemiluminescence (ECL) assay. Positive samples were confirmed using a quantitative radioimmunoprecipitation (RIP) assay. Positive cut-points were established for the ECL assay as 5 ng/mL as well as in terms of fixed raw counts, and for the RIP assay as 4 ng/mL. The results suggest significant antigenic differences between velaglucerase alfa and imiglucerase, with only 1% seroconversion rates against velaglucerase alfa.

"The combined data presented today provides additional and compelling support f
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
2. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
3. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
4. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
5. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
6. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
7. Shire Continues to Deliver Excellent Growth From Core Products
8. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
9. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
10. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
11. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced today ... financial results on Monday, August 10, 2015, prior to ... will host a conference call and live webcast with ... August 10, 2015. The financial results and ... section of the Company,s Web site at http://investors.impaxlabs.com ...
(Date:7/6/2015)... -- Mauna Kea Technologies (Euronext: MKEA, ... endomicroscopy platform, announced today it has obtained approval ... Health, Labor and Welfare (MHLW) for its unique ... miniprobe.   Used during endoscopy procedures, ... of a fiber-optic microscope that is small enough ...
(Date:7/6/2015)... , July 6, 2015  Protiviti, a global consulting ... Internal Auditing around the World publication ( www.protiviti.com/iaworld ... and reported on the evolution of the internal audit ... the globe as a means to providing senior executives ... this strategic business function. The 2015 edition ...
Breaking Medicine Technology:Impax to Report Second Quarter 2015 Results on August 10, 2015 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3New Edition of Internal Auditing Around the World from Protiviti Explores Changes and Trends 2
... Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, Differentiated ... Product Candidates, ... has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary Small Modular,ImmunoPharmaceutical ...
... Encouraging Response in CF Patients - Results Validate ... March 27 The Cystic Fibrosis Foundation,announced today that ... defect in CF, showed promising results in an ongoing ... mutation of CF. The drug is,being developed by Vertex ...
Cached Medicine Technology:Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3
(Date:7/7/2015)... ... 2015 , ... Each year the Holiday Inn Westbury donates many ... and international level; however, the Holiday Inn now hosts one large event at the ... the beneficiaries. In September of 2014 they hosted an event with all proceeds going ...
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile ... incidence of AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive ... in detection technologies and genetic engineering also open lucrative opportunities for the market ...
(Date:7/6/2015)... Cucamonga, Ca (PRWEB) , ... July 06, 2015 , ... ... distinguished awards in 2015, marking him as an attorney who has sharp ... Vargas received both a Client Distinction Award for 2015 from Martindale-Hubbell and a Top ...
(Date:7/6/2015)... ... , ... “ TapGlance ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... helps users visualize what rooms will look like before they even start renovating.. , ...
(Date:7/6/2015)... ... July 06, 2015 , ... In order to recognize and ... Society for Sports Medicine ( AOSSM ) will present ten research awards and ... a leader in orthopaedic sports medicine, AOSSM annually provides more than $350,000 to ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6
... auditory and visual aspects of speech can be processed much ... hearing impairment, if the cochlear implant is carried out at ... implants. About 36 profoundly deaf children aged between 5 years ... had received the cochlear implant for a period of one ...
... study conducted to determine the effectiveness of 27 different ... seeds and pistachio nuts have been found to have ... phytosterol (plant chemicals which reduce cholesterol levels and improve ... cholesterol lowering agent and thereby improve cardiac function. ...
... bystanders to good Samaritans in situations that are dangerous or ... of people stand back and ignore a person in trouble ... ,But a new study, published in the European Journal ... to be in real danger, bystanders can become knights in ...
... color blindness due to X-chromosome variations, which make ... an increased sensitivity to differentiate two color dimensions//, ... persons. The results of these studies carried out ... Cambridge had been published in the Journal Current ...
... of Birmingham tested the 'Bambach Saddle Seat' invented by Australian ... relieve backache//. ,The chair, which is priced at 399 ... 'S' shape and positions the pelvis correctly. ,Each ... their pelvis tilt backwards slightly and given a task to ...
... cancer fighting properties. But these properties of the vegetable ... their genetic make-up, according to an Institute// of Food ... scientists are now creating a "super-broccoli." This contains a ... hence is available in increased amounts to the body. ...
Cached Medicine News:Health News:Early Cochlear Implants Prove To Be Effective 2Health News:Colorblind Individuals have expanded color vision 2Health News:New Chair Invented To Relieve Backache 2Health News:“Super Broccoli” Could Confer Better Cancer Protecti 2
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
...
Medicine Products: